| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1832 | 2020 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 287 | 2021 |
| Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma VS Koshkin, PC Barata, T Zhang, DJ George, MB Atkins, WJ Kelly, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 174 | 2018 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 170 | 2021 |
| Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain A Bakshi, CA Keck, VS Koshkin, DG LeBold, R Siman, EY Snyder, ... Brain research 1065 (1-2), 8-19, 2005 | 123 | 2005 |
| Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin CE Chu, M Sjöström, EA Egusa, EA Gibb, ML Badura, J Zhu, VS Koshkin, ... Clinical Cancer Research 27 (18), 5123-5130, 2021 | 84 | 2021 |
| Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance PC Barata, VS Koshkin, P Funchain, D Sohal, A Pritchard, S Klek, ... Annals of Oncology 28 (10), 2458-2463, 2017 | 78 | 2017 |
| Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook D Gopalakrishnan, VS Koshkin, MC Ornstein, A Papatsoris, P Grivas Therapeutics and clinical risk management, 1019-1040, 2018 | 66 | 2018 |
| Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT# 02844816). PC Black, C Tangen, P Singh, DJ McConkey, S Lucia, WT Lowrance, ... Journal of Clinical Oncology 38 (15_suppl), 5022-5022, 2020 | 58 | 2020 |
| Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target VS Koshkin, JA Garcia, J Reynolds, P Elson, C Magi-Galluzzi, ... Clinical Cancer Research 25 (1), 210-221, 2019 | 56 | 2019 |
| Emerging role of immunotherapy in advanced urothelial carcinoma VS Koshkin, P Grivas Current oncology reports 20, 1-10, 2018 | 53 | 2018 |
| HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer M Alyamani, H Emamekhoo, S Park, J Taylor, N Almassi, S Upadhyay, ... The Journal of clinical investigation 128 (8), 3333-3340, 2018 | 50 | 2018 |
| Racial disparities in COVID-19 outcomes among black and white patients with cancer J Fu, SA Reid, B French, C Hennessy, C Hwang, NT Gatson, N Duma, ... JAMA network open 5 (3), e224304-e224304, 2022 | 47 | 2022 |
| A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, NJ Miller, L Carril-Ajuria, ... European urology oncology 4 (3), 464-472, 2021 | 46 | 2021 |
| TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells J Chou, K Trepka, M Sjöström, EA Egusa, CE Chu, J Zhu, E Chan, ... European urology oncology 5 (6), 714-718, 2022 | 43 | 2022 |
| Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19 AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, ... JAMA network open 4 (11), e2134330-e2134330, 2021 | 40 | 2021 |
| Systematic review: targeting HER2 in bladder cancer VS Koshkin, P O’Donnell, EY Yu, P Grivas Bladder Cancer 5 (1), 1-12, 2019 | 39 | 2019 |
| Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study VS Koshkin, N Henderson, M James, D Natesan, D Freeman, A Nizam, ... Cancer 128 (6), 1194-1205, 2022 | 36 | 2022 |
| Feasibility of cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with diminished renal function VS Koshkin, PC Barata, LA Rybicki, H Zahoor, N Almassi, AM Redden, ... Clinical genitourinary cancer 16 (4), e879-e892, 2018 | 32 | 2018 |
| Patient characteristics, treatment patterns and prognostic factors in squamous cell bladder cancer H Zahoor, P Elson, A Stephenson, GP Haber, J Kaouk, A Fergany, B Lee, ... Clinical Genitourinary Cancer 16 (2), e437-e442, 2018 | 32 | 2018 |
Pedro BarataAssociate Professor, University Hospitals Seidman Cancer Center, Case Western UniversityVerified email at UHhospitals.org
